Salk Institute for Biological Studies: This Time, It's Personal - Enhancing Patient Response to Cancer Immunotherapy
May 16, 2024
May 16, 2024
LA JOLLA, California, May 16 (TNSres) -- The Salk Institute for Biological Studies issued the following news release:
* * *
Salk researchers uncover why patients with ARID1A mutations are more likely to respond to cancer immunotherapy; findings could improve future cancer care and drug development
* * *
Immunotherapy has revolutionized the way we treat cancer in recent years. Instead of targeting the tumor itself, immunotherapies work by direct . . .
* * *
Salk researchers uncover why patients with ARID1A mutations are more likely to respond to cancer immunotherapy; findings could improve future cancer care and drug development
* * *
Immunotherapy has revolutionized the way we treat cancer in recent years. Instead of targeting the tumor itself, immunotherapies work by direct . . .